|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.58 USD | +3.02% |
|
+1.41% | -7.23% |
| 01-12 | Xenon Pharmaceuticals Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:00 AM | |
| 12-15 | Global markets live: iRobot, Cencora, Franklin Resources, Sanofi, Enel… |  |
| Capitalization | 3.12B 2.68B 2.49B 2.32B 4.33B 281B 4.67B 28.67B 11.27B 135B 11.7B 11.46B 494B | P/E ratio 2025 * |
-9.52x | P/E ratio 2026 * | -8.78x |
|---|---|---|---|---|---|
| Enterprise value | 2.62B 2.25B 2.1B 1.95B 3.64B 237B 3.93B 24.13B 9.49B 113B 9.84B 9.64B 416B | EV / Sales 2025 * |
350x | EV / Sales 2026 * | 141x |
| Free-Float |
98.94% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Xenon Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | +3.02% | ||
| 1 week | +1.41% | ||
| Current month | -7.23% | ||
| 1 month | -5.63% | ||
| 3 months | +3.98% | ||
| 6 months | +29.09% | ||
| Current year | -7.23% |
| 1 week | 39.98 |  | 43.76 |
| 1 month | 39.98 | | 46.36 |
| Current year | 39.98 | | 45.24 |
| 1 year | 26.74 | | 46.6 |
| 3 years | 26.74 | | 50.99 |
| 5 years | 13.98 | | 50.99 |
| 10 years | 2.1 | | 50.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ian Mortimer
CEO | Chief Executive Officer | 50 | 02/06/2021 |
Tucker Kelly
DFI | Director of Finance/CFO | 55 | 14/10/2025 |
Matthew Ronsheim
COO | Chief Operating Officer | 54 | 11/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Gary Patou
BRD | Director/Board Member | 67 | 31/12/2003 |
Steven Gannon
BRD | Director/Board Member | 64 | 20/05/2015 |
Dawn Svoronos
CHM | Chairman | 72 | 31/05/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.02% | +1.41% | +8.71% | +14.86% | 3.12B | |
| -0.89% | +0.70% | +6.80% | +86.25% | 49.64B | |
| -1.15% | +7.43% | +94.47% | +13.63% | 44.64B | |
| -0.16% | -6.63% | +137.14% | +740.41% | 34.92B | |
| +1.80% | +11.24% | -4.06% | -24.77% | 26.9B | |
| +4.89% | +6.38% | +44.02% | -18.56% | 20.59B | |
| +0.55% | +17.30% | +136.69% | -44.90% | 21.08B | |
| +2.32% | +2.49% | +122.74% | +153.39% | 14.24B | |
| -3.00% | +5.76% | +177.12% | - | 14.37B | |
| +5.00% | -5.41% | -2.89% | +267.71% | 12.96B | |
| Average | +1.24% | +2.55% | +72.07% | +132.00% | 24.25B | |
| Weighted average by Cap. | +0.51% | +2.97% | +71.37% | +151.04% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 7.5M 6.44M 6M 5.58M 10.41M 677M 11.23M 68.95M 27.11M 324M 28.13M 27.55M 1.19B | 18.48M 15.87M 14.77M 13.75M 25.65M 1.67B 27.67M 170M 66.78M 797M 69.28M 67.86M 2.93B |
| Net income | -337M -289M -269M -251M -468M -30.39B -504M -3.1B -1.22B -14.53B -1.26B -1.24B -53.34B | -396M -340M -317M -295M -550M -35.76B -594M -3.64B -1.43B -17.1B -1.49B -1.46B -62.76B |
| Net Debt | -494M -424M -395M -368M -686M -44.58B -740M -4.54B -1.79B -21.32B -1.85B -1.81B -78.24B | -520M -446M -416M -387M -722M -46.91B -779M -4.78B -1.88B -22.43B -1.95B -1.91B -82.33B |
More financial data
* Estimated data
Employees
322
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/01/26 | 41.58 $ | +3.02% | 1,196,847 |
| 13/01/26 | 40.36 $ | -2.11% | 698,864 |
| 12/01/26 | 41.23 $ | -2.18% | 1,253,714 |
| 09/01/26 | 42.15 $ | +2.26% | 2,055,936 |
| 08/01/26 | 41.22 $ | -2.14% | 1,014,226 |
Delayed Quote Nasdaq, January 14, 2026 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
40.36USD
Average target price
55.51USD
Spread / Average Target
+37.53%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- XENE Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition